Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 1/20 | 0.52 |
| ▸ | CDK2 | P24941 | 1/20 | 0.52 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.52 |
| ▸ | GSK3B | P49841 | 3/20 | 0.48 |
| ▸ | GSK3A | P49840 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4421326 | 0.86 | LMNA (0.42) | ADORA3ADORA1ADORA2AALDH1A1MAPT | |
| SCHEMBL28137717 | 0.83 | TSHR (0.50) | GSK3BCYP2C19MAPT | |
| SCHEMBL13041347 | 0.81 | DEGS1 (0.46) | MAPK1 | |
| SCHEMBL20503498 | 0.80 | JAK2 (0.35) | CCNA2CDK2CCNA1TP53 | |
| SCHEMBL6684465 | 0.79 | CCNA2 (0.33) | CCNA2CDK2CCNA1GSK3BGSK3A | |
| SCHEMBL6917924 | 0.79 | ALDH1A1 (0.47) | ALDH1A1MAPK1MAPT | |
| Hydrochloric Acid SCHEMBL9140040 | 0.78 | CCNA2 (0.33) | CCNA2CDK2CCNA1GSK3BGSK3A | |
| SCHEMBL2955585 | 0.78 | ALDH1A1 (0.51) | ALDH1A1MAPTHPGD | |
| SCHEMBL4794477 | 0.78 | SMN1; SMN2 (0.58) | TP53ADORA3ADORA1ADORA2AALDH1A1 | |
| SCHEMBL9140019 | 0.77 | GSK3A (0.34) | CCNA2CDK2CCNA1GSK3BGSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9296698-B2 | Amino heteroaryl compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20120329830-A1 | Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use | AMGEN INC. (US) | 2012-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329830-A1 | Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use | BACE1, BACE2, APP | CCNA2 1269/4885CDK2 324/4885CCNA1 941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.